aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference
May 31 2018 - 8:00AM
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel immunological pathways, today announced that Sanjay Shukla,
M.D., M.S., President and Chief Executive Officer, will present at
the Jefferies 2018 Global Healthcare Conference in New York City on
Thursday, June 7, 2018 at 9:30 a.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may
be accessed on the aTyr website events page at:
http://investors.atyrpharma.com/events-and-webcasts. An audio
replay will be available for 90 days following the event.
About aTyr Pharma
aTyr is a clinical-stage biotechnology company engaged in the
discovery and clinical development of innovative medicines using
its knowledge of tRNA synthetase biology. The company is focused on
the therapeutic translation of the Resokine pathway, comprised of
extracellular proteins derived from the histidyl tRNA synthetase
(HARS) gene family. aTyr’s clinical stage ATYR1923 candidate
augments the Resokine pathway and is designed to temper immune
engagement in interstitial lung diseases. aTyr’s immuno-oncology
research program targets the Resokine pathway using antibodies to
enhance the immune response in tumor settings. aTyr has built an
intellectual property estate, to protect its pipeline, comprising
over 250 issued patents or allowed patent applications that are
owned or exclusively licensed, including over 300 potential protein
compositions derived from tRNA synthetase genes. For more
information, please visit http://www.atyrpharma.com.
Contact: |
Mark Johnson |
Sr. Director, Investor
Relations |
mjohnson@atyrpharma.com |
858-223-1163 |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024